{
  "patient_data": "note\":\"  *** *, ****    NAME: **** *****    MRN: *********  DOB: */*/****  AGE: 44 y.o.       ******* * ***********  *** ********** **** ** *** *  ***** ***** ** *****                                               Diagnosis: SCC of ***********  Stage: ******* - *** - negative margins, no ***      HPI:  **** ***** is a 44 y.o. male who  who was seen by a local specialist for an evaluation of his left neck mass. A CT of the neck done ** *-*-** showed asymmetric activity with fullness on the left tongue base and ********** with *** SUV of 9.1. There was also an overlying level II node 2.8x 3.3cm w/ SUV of 20 and 2 additional smaller level II LNs with SUV up to 11. In the inferior neck on the left is a ***** node subjacent to SCM at level of hyoid bone with SUV of 5.7. Left neck FNA showed p16+ SCC. He underwent direct laryngoscopy with biopsy */*/** showed left tonsillar p16+ SCC of the tonsils. He underwent neck dissection on *-**-** w/ */**+ LNs (largest 5.2cm), no *** and transoral robotic surgery ( TORS) with the ** ***** surgical system on *-**-** w/ a 1.5 cm invasive SCC of the palatine *******/*** with negative margins.",
  "ai_note": {
    "recommendation": "recommended",
    "reasoning": "The patient presents with a history of squamous cell carcinoma (SCC) of the tonsils and tongue base at age 44.  While SCC is not inherently linked to a single rare genetic syndrome, the early onset (age 44) raises suspicion for a predisposition syndrome that increases cancer risk.  The provided literature mentions several syndromes associated with increased head and neck cancer risk, including but not limited to:  \n\n* **Li-Fraumeni syndrome:** This syndrome is associated with a variety of cancers, including sarcomas, breast cancer, brain tumors, and leukemia, and can sometimes manifest with early-onset head and neck cancers.  However, the information provided does not include a family history of cancer, which is a key feature of Li-Fraumeni syndrome. \n* **Cowden syndrome:** This syndrome is associated with an increased risk of various cancers, including breast cancer and thyroid cancer, and also includes hamartomatous polyps.  The patient's age at diagnosis of SCC is consistent with Cowden syndrome, but other features of the syndrome are absent from the provided data. \n* **Other Syndromes:** The literature mentions other syndromes with head and neck manifestations, but the information provided is insufficient to assess their relevance to this patient's case.  \n\nGiven the early onset of SCC, genetic testing is recommended to explore potential underlying genetic predispositions.  This testing could include panels for genes associated with cancer predisposition syndromes, such as those mentioned above, or a broader genomic approach depending on the available resources and clinical judgment.  Further investigation into family history of cancer is crucial to refine the differential diagnosis and guide genetic testing.",
    "confidence": "60%",
    "timestamp": "2025-03-22T15:26:02.234541"
  },
  "retrieved_docs": [
    {
      "id": "m-hfm-ov_txt_33",
      "contents": " PubMed PMID: 24268655.   \nGorlin RJ, Cohen MM, Hennekam RCM. Syndromes of the Head and Neck. 4 ed. Oxford, UK: Oxford University Press; 2001.   \n",
      "token_count": 44,
      "sentence_count": 4
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_515",
      "contents": "Peutz-Jeghers\u2013type hamartomatous polyps in the small intestine as well as in the stomach, large bowel, and extraintestinal sites, including the renal pelvis, bronchus, gallbladder, nasal passages, urinary bladder, and ureters Pigmented macules on the face, around oral mucosa and the perianal region, most pronounced in childhood \nCowden Syndrome \nEarly-onset breast cancer, particularly before age 40   \nMacrocephaly, especially $63~\\mathrm{cm}$ or larger in males,   \n$60~\\mathrm{cm}$ or larger in females   \nThyroid cancer, particularly follicular type, before   \nage 50   \nGoiter, Hashimoto thyroiditis   \nDysplastic gangliocytoma of the cerebellum (Lhermitte  \nDuclos disease)   \nIntestinal hamartomas   \nEsophageal glycogenic acanthosis   \nSkin findings of tricholemmomas or penile freckling   \nPapillomas of oral cavity \n\\*From Tinat J, Bougeard G, Baert-Desurmont S, et al: 2009 Version of the Chompret criteria for Li Fraumeni syndrome, J Clin Oncol 27:e108, 2009. \nto also show the extracolonic manifestations of Gardner syndrome, the same mutation in unrelated individuals has been found to cause only FAP in one individual and Gardner syndrome in another. Thus whether or not an individual has FAP or Gardner syndrome is not simply due to which mutation is present in the $A P C$ gene but is likely affected by genetic variation elsewhere in the genome. \nLynch Syndrome. Approximately $2\\%$ to $4\\%$ of cases of colon cancer are attributable to LS      (Case 29). LS is characterized by autosomal dominant inheritance of colon cancer in association with a small number of adenomatous polyps that begin during early adulthood. The number of polyps is generally quite small, in contrast to the hundreds to thousands of adenomatous polyps seen with FAP. Nonetheless, the polyps in LS have high potential to undergo malignant transformation.",
      "token_count": 458,
      "sentence_count": 21
    },
    {
      "id": "mdel17q21_31_txt_34",
      "contents": " 2006;38:1032-7. PubMed PMID: 16906163.   \n",
      "token_count": 18,
      "sentence_count": 2
    },
    {
      "id": "fragilex_txt_61",
      "contents": " 2014;3:153\u201361. PubMed PMID: 25606365. \nChapter Notes \nAuthor History \n",
      "token_count": 22,
      "sentence_count": 4
    },
    {
      "id": "hrpt2_txt_17",
      "contents": " Preoperative assessment including labs and imaging (preoperative serum calcium and parathyroid hormone [PTH] levels, large or irregular gland size, or cystic features) can assist in distinguishing parathyroid adenoma involving a single gland and suspected parathyroid carcinoma. Preoperative biopsy via fne-needle aspiration should not be performed, as this can cause seeding of tumor tissue. Te optimal surgical approach includes preparation to perform complete gland removal and en bloc resection of surrounding structures if there are intraoperative fndings suggestive of parathyroid carcinoma. Experienced surgeons can usually distinguish normal parathyroid tissue from parathyroid adenomas and carcinomas intraoperatively. Normal parathyroid tissue is peanut butter colored, sof, small, and nonadherent to surrounding structures. Parathyroid adenomas are usually oval, round, or kidney shaped in appearance. Parathyroid carcinoma is usually hard/frm, white-gray, large, and intimately attached to surrounding structures [Authors, personal experience]. \nParathyroid adenoma involving a single gland can be resected. Multigland resection increases the risk for hypoparathyroidism with no true beneft of reducing disease recurrence. Terefore, subtotal parathyroidectomy is not recommended. Iacobone et al [2020] evaluated 20 individuals from three large families with hyperparathyroidism-jaw tumor (HPT-JT) syndrome; $95\\%$ had single-gland disease. Tese fndings supported unilateral parathyroid adenoma resection when preoperative imaging identifed the abnormal gland, although bilateral intraoperative exploration may be preferred in individuals with inconclusive or discordant preoperative imaging. Perrier et al [2020] recommended imaging to identify the abnormal gland followed by an open operation with inspection of both glands on the ipsilateral side. Contralateral exploration was not recommended if the fndings were congruent with preoperative imaging and the second ipsilateral gland was normal in appearance. \nParathyroid carcinoma.",
      "token_count": 452,
      "sentence_count": 15
    },
    {
      "id": "pnknd_txt_16",
      "contents": " PubMed PMID: 25572910. \n\nChapter Notes \nAuthor History \n",
      "token_count": 13,
      "sentence_count": 3
    },
    {
      "id": "spg15_txt_15",
      "contents": " PubMed PMID: 18332254.   \nChang J, Lee S, Blackstone C.",
      "token_count": 18,
      "sentence_count": 2
    },
    {
      "id": "men1_txt_54",
      "contents": "Sachithanandan N, Harle RA, Burgess JR (2005) Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 103:509-15 PubMed PMID: 15611976.   \nSakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, Imai T, Kaji H, Komoto I, Miura D, Yamada M, Uruno T, Horiuchi K, Miyauchi A, Imamura M (2012) Multiple endocrine neoplasia Type 1 in Japan: establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 76:533-9 PubMed PMID: 21950691.   \nScarsbrook AF, Ganeshan A, Statham J, Takker RV, Weaver A, Talbot D, Boardman P, Bradley KM, Gleeson FV, Phillips RR (2007) Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 27:455-77 PubMed PMID: 17374863.   \nSchaefer S, Shipotko M, Meyer S, Ivan D, Klose KJ, Waldmann J, Langer P, Kann PH (2008) Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Eur J Endocrinol 158:699-704 PubMed PMID: 18426829.   \nScheithauer BW, Kovacs K, Nose V, Lombardero M, Osamura YR, Lloyd RV, Horvath E, Pagenstecher A, Bohl JE, Tews DS. Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. Hum Pathol. 2009;40:270-8. PubMed PMID: 18755492.   \nSchnirer II, Yao JC, Ajani JA (2003) Carcinoid--a comprehensive review. Acta Oncol 42:672-92 PubMed PMID: 14690153.   \n",
      "token_count": 469,
      "sentence_count": 14
    },
    {
      "id": "achm_txt_38",
      "contents": " 2017;25:1210\u20136. PubMed PMID: 28812650.   \n",
      "token_count": 18,
      "sentence_count": 2
    },
    {
      "id": "hrpt2_txt_34",
      "contents": "Nel C, Yakoob Z, Schouwstra CM, van Heerden WF. Familial forid cemento-osseous dysplasia: a report of three cases and review of the literature. Dentomaxillofac Radiol. 2021;50:20190486. PubMed PMID: 32315206.   \nNewey PJ, Bowl MR, Cranston T, Takker RV. Cell division cycle protein 73 homolog (CDC73) pathogenic variants in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010;31:295-307. PubMed PMID: 20052758.   \nPanicker LM, Zhang JH, Dagur PK, Gastinger MJ, Simonds WF. Defective nucleolar localization and dominant interfering properties of a parafbromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome. Endocr Relat Cancer. 2010;17:513-24. PubMed PMID: 20304979.   \nPerrier ND, Arnold A, Costa-Guda J, Busaidy NL, Nguyen H, Chuang HH, Brandi ML. Hereditary endocrine tumours: current state-of-the-art and research opportunities: new and future perspectives for parathyroid carcinoma. Endocr Relat Cancer. 2020;27:T53-T63. PubMed PMID: 32449693.   \nPichardo-Lowden AR, Manni A, Saunders BD, Baker MJ. Familial hyperparathyroidism due to a germline pathogenic variant of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk. Endocr Pract. 2011;17:602-9. PubMed PMID: 21324824.   \nPimenta FJ, Gontijo Silveira LF, Tavares GC, Silva AC, Perdigao PF, Castro WH, Gomez MV, Teh BT, De Marco L, Gomez RS. HRPT2 gene alterations in ossifying fbroma of the jaws. Oral Oncol.",
      "token_count": 481,
      "sentence_count": 26
    },
    {
      "id": "rotor_txt_15",
      "contents": " PubMed PMID: 22232210. \nChapter Notes \nRevision History \n",
      "token_count": 13,
      "sentence_count": 3
    },
    {
      "id": "propionic-a_txt_46",
      "contents": " 2012;16:230\u20134. PubMed PMID: 22151065.   \n",
      "token_count": 17,
      "sentence_count": 2
    },
    {
      "id": "dbh_txt_23",
      "contents": "PubMed PMID: 11170900. \n\nChapter Notes \nAuthor History \n",
      "token_count": 13,
      "sentence_count": 3
    },
    {
      "id": "syne1ca-ar_txt_24",
      "contents": " PubMed PMID: 17761684. \nChapter Notes \nAuthor History \n",
      "token_count": 13,
      "sentence_count": 3
    },
    {
      "id": "mdef-cmd_txt_40",
      "contents": " 2010;25:1559\u201381. PubMed PMID: 21078917. \n",
      "token_count": 19,
      "sentence_count": 2
    },
    {
      "id": "ipa_txt_24",
      "contents": " 2014;370:1065\u20137. PubMed PMID: 24571725.   \n",
      "token_count": 18,
      "sentence_count": 2
    },
    {
      "id": "men1_txt_25",
      "contents": "\u2022 Surgery is usually indicated for insulinoma and most of the other pancreatic tumors observed in MEN1. According to Tonelli et al [2005], the best surgical approach for a MEN1-associated insulinoma is intraoperative localization of nodules $>{\\sim}0.5~\\mathrm{cm}$ in diameter by palpation or intraoperative ultrasound followed either by enucleation (removal) of these nodules or by pancreatic resection if multiple large deep tumors are present.   \n\u2022 Te optimal therapy of gastrinoma is controversial. \u26ac In non-metastasizing gastrinoma within the pancreas, surgery may be curative and should be performed by an experienced endocrine surgeon. Individuals with MEN1 will have multiple small submucosal duodenal gastrinomas and in experienced surgical centers local excision of these tumors with lymph node dissection, duodenectomy, or less commonly duodenopancreatectomy may also be considered together with the afected individual's preferences, as such approaches may improve the cure rate. However, given the common multiple microadenomas typical of these tumors in individuals with MEN1, surgery is ofen not efective. \u26ac Whipple pancreaticoduodenectomy provides the greatest likelihood of cure for gastrinoma in individuals with MEN1 but can be associated with an increased operative mortality and long-term morbidity unless performed by an experienced surgeon.   \n\u2022 Unresectable tumors or advanced metastatic cancer can be treated with somatostatin analogs (SSAs), cytotoxic chemotherapy, inhibitors of tyrosine kinase receptors (sunitinib), or inhibitors of mammalian target of rapamycin (mTOR; everolimus). All these therapies have demonstrated an increase in the median progression-free survival in individuals with sporadic pancreatic neuroendocrine tumors; however, no specifc trials have been performed in individuals with MEN1 who have GEP tract tumors [Marini et al 2017].   \n\u2022 Treatment for nonfunctioning pancreatic neuroendocrine tumors is controversial; some centers consider surgical resection for lesions ${>}1$ cm in size, while other centers recommend surgery only for tumors ${>}2$ cm.   \n\u2022 Occult metastatic disease (i.e.",
      "token_count": 501,
      "sentence_count": 12
    },
    {
      "id": "pp-blastoma_txt_24",
      "contents": " Proper placement of needle and catheter can be difcult without radiographic guidance. \nSurgery for metastases. Brain parenchyma is the most common distant metastatic site for PPB. Resection is strongly suggested for intracranial mass lesion(s). Several individuals in whom cerebral PPB metastases have been resected have survived [Priest et al 2007, Nakano et al 2019a]. \nRadiation therapy is used primarily to treat PPB recurrence or metastasis, or in the setting of local control of residual, unresectable tumor [Priest et al 1997, Kamenova et al 2006, Indolf et al 2007, Williams et al 2012]. Radiation may also be used as local control for other manifestations of PPB such as brain metastases. \nTreatment for recurrence requires an individualized approach. Additional information regarding treatment and results from a uniformly treated cohort of individuals with PPB is available from the International PPB/DICER1 Registry (www.PPBregistry.org; dicer1@childrensmn.org). \nMultinodular goiter (MNG) and thyroid cancer \n\u2022 Observation with or without biopsy. Te approach to preoperative investigation is the same for individuals with a sporadic nodule with or without a DICER1 pathogenic variant. See guidelines (available for purchase) from the American Tyroid Association and from the American Association of Clinical Endocrinologists / American College of Endocrinolgy / Associazione Medici Endocrinologi collaborative [Gharib et al 2016] (full text).   \n\u2022 Ultrasound examination is used to confrm the presence and characteristics of the nodule(s) and to determine the need for fne needle aspiration biopsy (FNA) [Francis et al 2015, American College of Radiology]. FNA of smaller nodules should be considered in individuals with a history of previous radiation exposure and/or concerning sonographic features including (but not limited to) solid composition, hypoechoic echotexture, taller-than-wide shape on transverse imaging, spiculated/lobulated or invasive margins, hyperechoic foci consistent with microcalcifcations, and abnormal lymph nodes.",
      "token_count": 470,
      "sentence_count": 17
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_529",
      "contents": "First, it increases our ability to discriminate between different tumors in ways that complement the standard criteria applied by pathologists to characterize tumors, such as histological appearance, cytogenetic markers, and expression of specific marker proteins. Once distinguishing signatures for different tumor types (e.g., tumor A versus tumor B) are defined using known samples, the expression pattern of unknown tumor samples can then be compared with the expression signatures for tumor A and tumor B and classified as A-like, B-like, or neither, depending on how well their expression profiles match the signatures of A and B. Pathologists have used expression profiling to make difficult distinctions between tumors that require very different management approaches. These include distinguishing large B-cell lymphoma from Burkitt lymphoma, differentiating primary lung cancers from squamous cell carcinomas of the head and neck metastatic to lung, and identifying the tissue of origin of a cryptic primary tumor whose metastasis gives too little information to allow its classification. \n\n\u2022 Second, different signatures may be found to correlate with known clinical outcomes, such as prognosis, response to therapy, or any other outcome of interest. If validated, such signatures can be applied prospectively to help guide therapy in newly diagnosed patients. \nFinally, for basic research, clustering may reveal previously unsuspected connections of functional importance among genes involved in a disease process. \nGene Expression Profiling in Cancer Prognosis \nChoosing the appropriate therapy for most cancers is difficult for patients and their physicians alike, because recurrence is common and difficult to predict. Better characterization of each patient\u2019s cancer as to recurrence risk and metastatic potential would clearly be beneficial for deciding between more or less aggressive courses of surgery and/or chemotherapy. For example, in breast cancer, although presence of the estrogen and progesterone receptors, amplification of the human epidermal growth factor receptor 2 (HER2) oncogene, and absence of metastatic tumor in lymph nodes found on dissection of axillary lymphatics are strong predictors of better response to therapy and prognosis, they are still imprecise. Expression profiling (Fig.",
      "token_count": 458,
      "sentence_count": 13
    },
    {
      "id": "fap_txt_2",
      "contents": " Relative indications for colectomy include presence of multiple adenomas larger than $10\\;\\mathrm{mm}$ that cannot be reasonably removed endoscopically, a signifcant increase in adenoma number between surveillance exams, presence of adenomas with high-grade dysplasia, or inability to adequately survey the colon (e.g., due to innumerable diminutive adenomas or limited access to or compliance with colonoscopy). Endoscopic or surgical removal of duodenal adenomas is considered if polyps exhibit villous change or severe dysplasia, exceed 1 cm in diameter, or exhibit advanced stage using Spigelman scoring system. Gastrectomy is considered if advanced gastric neoplasia is found on upper endoscopy. Osteomas may be removed for cosmetic reasons. Desmoid tumors may be surgically excised or treated with nonsteroidal antiinfammatory drugs (NSAIDs), anti-estrogens, cytotoxic chemotherapy, and/or radiation if at advanced stage. Standard treatment when needed for adrenal masses and thyroid carcinoma. Several studies have shown that NSAIDs and erlotinib have caused regression of adenomas and decreased the polyp burden in individuals with FAP, though there are currently no FDA-approved chemopreventive agents for FAP, given an unclear efect on subsequent cancer risk. \nPrevention of primary manifestations: Colectomy to reduce the risk for CRC in individuals with classic FAP. For individuals with attenuated FAP, colectomy may be necessary, but in approximately one third of individuals, the colonic polyps are limited enough in number that surveillance with periodic colonoscopic polypectomy is sufcient to prevent CRC. It is currently unknown if prophylactic gastrectomy should be considered in individuals with GAPPS. \nSurveillance: Colorectal screening by colonoscopy every one to two years beginning at age ten to 15 years for classic FAP and in late adolescence for attenuated FAP; esophagogastroduodenoscopy with visualization of the ampulla of Vater by age 20 to 25 years or prior to colon surgery, with consideration of complete small bowel visualization in the setting of advanced Spigelman stage.",
      "token_count": 494,
      "sentence_count": 12
    },
    {
      "id": "fap_txt_18",
      "contents": "National Comprehensive Cancer Network (NCCN) [Weiss et al 2021] (full text) \u2022 American Society for Gastrointestinal Endoscopy [Yang et al 2020] (full text) \u2022 American College of Gastroenterology [Syngal et al 2015] (full text) \u2022 American Society of Colon and Rectal Surgeons [Herzig et al 2017] (full text) American Society of Clinical Oncology [Stofel et al 2015] (full text) British Society of Gastroenterology [Monahan et al 2020] (full text) Society of Surgical Oncology [Guillem et al 2006] (full text) \n\u2022 Desmoid Tumor Working Group [2020] (full text) European Society of Gastrointestinal Endoscopy [van Leerdam et al 2019] (full text) \nColonic polyps. For individuals with FAP, endoscopic surveillance with colonoscopy is generally recommended to start between ages ten and 15 years with an interval of every one to two years [Weiss et al 2016, van Leerdam et al 2019, Yang et al 2020]. All polyps $>\\!5\\;\\mathrm{mm}$ should be resected. If the polyp burden is manageable and no defnitive indications for surgery are noted, it is reasonable to delay colectomy and monitor with endoscopic surveillance [Ishikawa et al 2016]. Absolute indications for colectomy include documented or suspected colorectal cancer (CRC) or signifcant symptoms (e.g., obstruction, bleeding), although these are uncommon in the absence of cancer. Relative indications for colectomy include presence of multiple large adenomas $(>\\!10\\;\\mathrm{mm})$ ) that cannot be reasonably managed by endoscopy, a signifcant increase in adenoma number between surveillance examinations, presence of adenomas with high-grade dysplasia, or inability to adequately survey the colon (e.g., due to innumerable diminutive adenomas or limited access or compliance with colonoscopy). In individuals age ten to 20 years in whom adenomas are $<\\!",
      "token_count": 466,
      "sentence_count": 13
    },
    {
      "id": "pp-blastoma_txt_25",
      "contents": " FNA results that show benign-appearing follicular cells (including H\u00fcrthle cells and/or lymphocytes) indicate (in most cases) nodular hyperplasia, follicular adenoma, or lymphocytic thyroiditis. Continued follow-up care is appropriate in the presence of a stable nodule(s).   \n\u2022 Surgery is appropriate for symptomatic nodules, nodules with signifcant growth on serial US examination, or nodules with abnormal cytology based on the Bethesda System for Reporting Tyro id Cytology [Pusztaszeri et al 2016]. If the results of the FNA are positive for papillary thyroid carcinoma, total thyroidectomy is the treatment of choice for individuals who are surgical candidates.   \n\u2022 Radioactive iodine is the most efective medical treatment for individuals found to have distant (lung) metastasis or persistent disease not amenable to repeat surgery. \nOvarian Sex Cord\u2013Stromal Tumors \nOvarian sex cord-stromal tumors (including Sertoli-Leydig cell tumor [SLCT] and gynandroblastoma) are rare and few studies have focused on clinical variables, treatment, and prognosis. Treatment regimens are based on those used for ovarian germ cell tumors and data are limited [Schneider et al 2002, Schultz et al 2012, Schultz et al 2017]. \n\nIf imaging or laboratory studies suggest the presence of an ovarian tumor, consultation with specialists in gynecologic oncology is suggested. Surgical resection with staging procedures is usually the initial treatment. Fertility-sparing surgery is recommended for most girls and young women. \nMost individuals undergo unilateral salpingo-oophorectomy with sampling of peritoneal fuid and cytologic examination of peritoneal washings. Lymph nodes should be assessed radiographically, carefully examined intraoperatively, and removed if they are clinically concerning. Level of diferentiation and stage infuen ce outcome and are critical to determining whether adjuvant therapy is necessary. Efort must be made to avoid rupture of the tumor as this would result in an increased stage for some individuals.",
      "token_count": 468,
      "sentence_count": 15
    },
    {
      "id": "pp-blastoma_txt_28",
      "contents": " NCMH is usually managed by complete surgical resection. When access to the tumor is adequate, one approach is endonasal endoscopy with resection. If complete resection is difcult, these tumors can be efectively debulked in most cases; however, complete extirpation is preferred. \nEmbryonal rhabdomyosarcoma (ERMS) of the cervix may not require hysterectomy since these tumors are usually confned to the cervix and typically do not have deep stromal invasion. Local resection followed by chemotherapy appropriate for ERMS is one management approach. On completion of chemotherapy, biopsies are performed to determine if residual viable tumor is present. Te decision for additional treatment is based on the results of the post-chemotherapy biopsies and follow-up imaging studies. \nPituitary blastoma. Surgical resection is the mainstay of management. Among the cases described in the literature, adjuvant, usually multiagent chemotherapy with or without radiation therapy has also been described [Scheithauer et al 2012]. Normalization of endocrine laboratory values, especially ACTH, is expected postoperatively and is a useful marker of disease activity. \nPineoblastoma. Immediate management issues may include interventions for obstructive hydrocephalus. Open resection, rather than biopsy, is the treatment of choice and an aggressive surgical approach is associated with prolonged survival. Following maximal surgical resection, standard adjuvant therapy includes fractionated radiotherapy (to brain and spine) and chemotherapy [Tate et al 2011]. Tis combination has been reported to lead to progression-free survival of $60\\%.70\\%$ in nonmetastatic pineoblastoma, while survival remains poor for young children who do not receive radiotherapy [Mynarek et al 2017]. \nDICER1-associated CNS sarcoma. Treatment aimed at gross total resection is central to management; the use of adjuvant radiation and multi-agent chemotherapy have also been described. \nSurveillance \nSurveillance guidelines for individuals with a germline DICER1 pathogenic variant have been established [Schultz et al 2018]. Provider and individual/family education is the cornerstone of surveillance. Individuals and caregivers should be advised of signs and symptoms of concern.",
      "token_count": 486,
      "sentence_count": 23
    },
    {
      "id": "pp-blastoma_txt_22",
      "contents": "\u2022 Radionuclide bone scan and/or PET scan to evaluate for metastatic disease and as a baseline relative to follow-up imaging   \n\u2022 Echocardiography as needed to defne intracardiac extension of tumor, tumor thrombi, or pericardial efusion   \n\u2022 Rarely, spine MRI for paraspinal or intraspinal extension   \n\u2022 In the event of systemic embolization and any suggestion of vascular involvement (facial plethora, vena cava syndrome, cardiac murmur), investigation with vascular ultrasound examination   \n\u2022 CT of the abdomen/pelvis to assess for liver or other intraabdominal metastases Note: Bone marrow involvement is extremely rare. \n\nOvarian sex cord-stromal tumors \n\u2022 When an ovarian sex cord-stromal tumor is suspected based on clinical features or individual or family history of DICER1, preoperative assessment of testosterone levels, AFP, inhibin A and B, and estradiol may be helpful in establishing one or more of these as a tumor marker.   \n\u2022 Intraoperative staging should be performed according to the International Federation of Gynecology and Obstetrics (FIGO) staging criteria and should include peritoneal cytology and assessment for preoperative or intraoperative rupture. Care should be taken to avoid rupturing the tumor if possible.   \n\u2022 Spread of ovarian sex cord-stromal tumors to the chest without extensive abdominopelvic disease is unlikely; however, baseline evaluation with chest CT is reasonable given the concern for synchronous conditions. \nCiliary body medulloepithelioma. Staging includes brain MRI to evaluate for direct intracranial extension and metastatic disease. \nBotryoid-type embryonal rhabdomyosarcoma of the cervix or other sites or ovarian sarcoma. Staging includes MRI or CT to evaluate extent of primary tumor and for presence of metastatic disease in lymph nodes, liver, and lungs. \nCentral nervous system (CNS) malignancies: pituitary blastoma, pineoblastoma, CNS sarcomas, and other intracranial tumors. Staging includes brain and spine MRI, and cerebrospinal fuid cytology examination. \nTreatment of Manifestations \nPleuropulmonary Blastoma (PPB) \n",
      "token_count": 481,
      "sentence_count": 18
    },
    {
      "id": "pp-blastoma_txt_29",
      "contents": " Note that if signs of tumor are detected, additional evaluation will be needed. Tis table is not intended to address post-tumor surveillance. \n\n",
      "token_count": 27,
      "sentence_count": 2
    },
    {
      "id": "men1_txt_37",
      "contents": "Tis chapter has been supported by Cofn MIUR 2003 (FM), by AIRC 2000 (MLB), and by the Fondazione Ente Cassa di Risparmio di Firenze (MLB). \nAuthor History \nMaria Luisa Brandi, MD, PhD (2005-present) \nAlberto Falchetti, MD, PhD; University Hospital of Careggi (2005-2012) \nFrancesca Giusti, MD, PhD (2012-present) \nFrancesca Marini, PhD (2005-present) \nRevision History \n\u2022 10 March 2022 (sw) Comprehensive update posted live 14 December 2017 (ma) Comprehensive update posted live   \n\u2022 12 February 2015 (me) Comprehensive update posted live 6 September 2012 (me) Comprehensive update posted live   \n\u2022 2 March 2010 (me) Comprehensive update posted live   \n\u2022 31 August 2005 (me) Review posted live 9 September 2004 (mlb) Original submission \nReferences \nPublished Guidelines / Consensus Statements \nTakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Available online. 2012. Accessed 8-24-23. \nLiterature Cited \nAl Brahim NY, Rambaldini G, Ezzat S, Asa SL (2007) Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology. Endocr Pathol 18:37-41 PubMed PMID: 17652799.   \nAlbers MB, Manoharan J, Bartsch D.K. Contemporary surgical management of the Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1. Best Pract Res Clin Endocrinol Metab. 2019;33:101318. PubMed PMID: 31521501.   \nAnlauf M, Enosawa T, Henopp T, Schmitt A, Gimm O, Brauckhof M, Dralle H, Musil A, Hauptmann S, Perren A, Kl\u00f6ppel G (2008) Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor.",
      "token_count": 484,
      "sentence_count": 25
    },
    {
      "id": "pp-blastoma_txt_8",
      "contents": " Five-year survival for type II PPB is $71\\%$ [Messinger et al 2015].   \n\u2022 Type III PPB is a purely solid, aggressive sarcoma which may present with respiratory distress and mediastinal shif. Type III PPB presents at a median age of 41 months. Children with type III PPB typically present with weight loss, fever, shortness of breath, and opacity on chest radiograph. Five-year survival for type III PPB is $53\\%$ [Messinger et al 2015].   \n\u2022 Type Ir (regressed or nonprogressed) PPB presents in individuals of any age and lacks a malignant component. Five-year survival for type Ir PPB is $100\\%$ [Messinger et al 2015]. \nTe natural history of PPB suggests that many tumors have a precancerous / early cancerous stage in the form of lung cysts. Although not all PPB lung cysts transform into high-grade sarcoma, no radiographic characteristics can yet identify which cysts will progress to sarcoma. Progression from cyst to sarcoma can occur quickly. When progression occurs, the mesenchymal cells of a type I PPB expand and overgrow the cyst septa and replace the cyst with a cystic and solid (type II) or purely solid (type III) sarcoma. Type I PPB has no metastatic potential, but individuals with type II or III PPB can present with or develop metastasis to the brain, bone, local thoracic lymph nodes, and liver. \nChildren with PPB type II or III may have tumor recurrence locally in the thorax and/or distant metastatic disease. Te brain, followed by bone, is the most common site of distant metastasis in PPB. Te outcome for these individuals is poor, although some have survived long-term [Priest et al 2007, Nakano et al 2019a]. \nMultinodular goiter (MNG) and thyroid cancer. Germline DICER1 pathogenic variants are associated with an increased risk of developing thyroid nodules and/or MNG.",
      "token_count": 453,
      "sentence_count": 17
    },
    {
      "id": "mccune-albright_txt_28",
      "contents": " Based on the 2012 International Consensus Guidelines for the management of intraductal papillary mucinous neoplasm (IPMNs) [Tanaka et al 2012]. Worrisome features include: pancreatitis; cyst $\\geq\\!3\\;{\\mathrm{cm}}$ ; thickened enhanced cystic walls; main pancreatic duct dilatation of $5{-}9\\;\\mathrm{mm}$ ; non-enhanced mural nodules; and abrupt change in caliber of the main pancreatic duct with distal pancreatic atrophy, lymphadenopathy, an elevated serum level of carbohydrate antigen (CA) 19-9, and a rapid rate of cyst growth $>\\!5\\;\\mathrm{mm}$ within two years. High-risk stigmata on CT, MRI, or EUS include: obstructive jaundice in afected individuals with a cystic lesion in the pancreatic head; enhanced solid component (mural nodule) within the cyst $\\left(\\geq5\\;\\mathrm{mm}\\right)$ ; and main pancreatic duct dilatation ${\\geq}10\\;\\mathrm{mm}$ . \n2. Te interval for repeat MRI/MRCP is not established [Gaujoux et al 2014, Wood et al 2017]. \nSurveillance \nDue to the mosaic nature of FD/MAS, the clinical fndings in afected individuals can vary signifcantly, with some individuals having involvement of only one organ system and others having more widespread involvement. Additionally, some features are age dependent and are either not likely to develop afer a certain age or are more likely to afect older individuals. Te following information on surveillance applies to individuals who have already been evaluated for signs and symptoms of the condition and in whom the extent of disease has been assessed; surveillance will need to be tailored to the individual's age and known afected organ systems (see Table 5). \nAgents/Circumstances to Avoid \nContact sports and other high-risk activities should be avoided in those with signifcant skeletal involvement. \nAvoid prophylactic optic nerve decompression (see Treatment of Manifestations). \n",
      "token_count": 481,
      "sentence_count": 13
    },
    {
      "id": "pp-blastoma_txt_23",
      "contents": "Type I PPB is treated with complete surgical removal with or without adjuvant chemotherapy. Te fve-ye ar overall survival for individuals with ytype I PPB is $89\\%$ ; the only PPB-related deaths in type I PPB have occurred following progression to type II or III PPB. Individuals with type Ir PPB are treated with resection alone (or observation in certain clinical circumstances including adulthood). PPB-related survival is $100\\%$ for individuals with type Ir PPB [Messinger et al 2015]. \nTypes II and III PPB are treated with aggressive surgical resection and intensive chemotherapy; fve-year overall survival is $71\\%$ and $53\\%$ for types II and III PPB respectively. Extent of disease may preclude initial surgical resection for some children with type II or III PPB. In these instances, biopsy followed by neoadjuvant chemotherapy followed by resection followed by subsequent chemotherapy has been performed. \nResection of PPB should be performed with care so as not to disrupt the tumor or induce tumor spill, similar to the care taken with removal of Wilms tumor. Since solid components of PPB are very friable, piecemeal removal and spill are ofen inevitable. \nIf it is evident at the time of surgery that the tumor has spread to the chest wall, pericardium, and/or diaphragm, removal of all grossly visible tumor is recommended. Sites of unresectable residual disease may be titanium \nclipped for radiographic localization and possible radiotherapy. Involvement of the diaphragm may require excision of a portion of the diaphragm and use of a Gore-Tex patch. \nDelayed resection afer chemotherapy is performed for tumors deemed unresectable at the time of diagnosis. Individuals receiving neoadjuvant chemotherapy may have marked tumor reduction; however, this response may be transient and tumor can recur rapidly. Chemotherapy alone is insufcient to eradicate solid PPB. \nIf gross-total resection is not achieved with the frst or second surgery, additional surgery may be required for local control. \nPleural efusions. Drainage of pleural efusions should be approached with caution. Solid tumors ofen invade the chest wall, obliterating the pleural space.",
      "token_count": 481,
      "sentence_count": 20
    },
    {
      "id": "retinoblastoma_txt_12",
      "contents": "\u2022 For very large tumors with risk factors for extraocular disease, bone marrow aspiration and examination of cerebrospinal fuid may also be performed at diagnosis, or when pathologic examination of the enucleated eye reveals optic nerve invasion or signifcant risks for extraocular extension.   \n\u2022 If retinoblastoma has spread outside the eye, the stage of cancer will be evaluated to determine the most appropriate care for the child.   \n\u2022 In individuals with a family history of retinoblastoma, and in uncommon circumstances in which the child presents with strabismus or poor vision, the retinal tumors may be small and detected by optical coherent tomography [Soliman et al 2017b].   \n\u2022 Consultation with a medical geneticist, certifed genetic counselor, or certifed advanced genetic nurse to inform afected individuals and their families about the nature, mode of inheritance, and implications of retinoblastoma can facilitate medical and personal decision making. \nTreatment of Manifestations \nGoals of treatment in order of priority are preservation of life and then sight. As optimal treatment may be complex, specialists skilled in the treatment of retinoblastoma from various felds including ophthalmology, pediatric oncology, pathology, and radiation oncology collaborate to deliver optimized care. \nIn addition to eye and tumor stage, choice of treatment depends on many factors, including the number of tumor foci (unifocal, unilateral multifocal, or bilateral), localization and size of the tumor(s) within the eye(s), presence of vitreous seeding, potential for useful vision, extent and kind of extraocular extension, and resources available. \nTreatment options for the eye include enucleation; cryotherapy; laser; systemic or local ocular chemotherapy, including intra-arterial chemotherapy, combined with or followed by laser or cryotherapy; radiation therapy using episcleral plaques; and, as a last resort, external beam radiotherapy. \nIf possible, radiation (including x-ray, CT scan, and external beam radiation) is avoided to minimize the lifetime risk of developing late-onset subsequent malignant neoplasms. Such tests may be used when critical in essential health care. \n",
      "token_count": 469,
      "sentence_count": 11
    },
    {
      "id": "hlrcc_txt_11",
      "contents": "\u2022 Early detection and surgical excision are critical at the frst sign of FH-related RCC. Expert opinion should be sought with a urologic oncology surgeon familiar with $F H$ tumor predisposition syndrome. Due to metastatic potential, lymph node dissection may be considered for staging even in the setting of small tumors.   \n\u2022 Given the aggressive nature of these tumors, only total nephrectomy was previously recommended. However, partial nephrectomy with a wide margin may be carefully considered in some settings when small, localized tumors may allow for complete excision (see NCI-PDQ\u00ae Genetics of Renal Cell Carcinoma).   \n\u2022 Consultation by an expert familiar with this syndrome is indicated.   \n\u2022 Non-surgical approaches such as surveillance, cryoablation, and radiofrequency ablation are not appropriate for the management of FH-related renal malignancies [Adams et al 2017]. \nSurveillance \nRegular surveillance with an emphasis on early detection of RCC by clinicians familiar with the clinical manifestations of FH tumor predisposition syndrome is recommended. Surveillance may also be considered for individuals with a suspected diagnosis in whom an $F H$ pathogenic variant has not been identifed, as well as for at-risk family members who have not undergone molecular genetic testing. Surveillance guidelines still require prospective validation, preferably in the context of international multicenter collaboration [Menko et al 2014, Schultz et al 2017]. \n1. Consensus recommendations for surveillance of RCC were developed in the context of an international HLRCC symposium. Renal ultrasound is not recommended for primary surveillance due to low sensitivity to detect small lesions [Menko et al 2014]. 2. MRI avoids radiation exposure, though gadolinium-based contrast agents \u2013 which are incompletely eliminated from the body \u2013 are currently used. However, there are currently no known adverse health efects from gadolinium retention in individuals with normal renal function. \n3. NCI-PDQ\u00ae Genetics of Renal Cell Carcinoma \n4. Te recommended age at which to begin renal surveillance has ranged signifcantly, from as early as age fve years [Alrashdi et al 2010] to adulthood [Lehtonen 2011, Smit et al 2011].",
      "token_count": 471,
      "sentence_count": 17
    },
    {
      "id": "pp-blastoma_txt_14",
      "contents": " Retinal abnormalities included pigmentary abnormalities, epiretinal membranes, drusen, and retinitis pigmentosa [Huryn et al 2019].   \n\u2022 Dental anomalies (e.g., bulbous crowns) \nSomatic mosaicism for a DICER1 pathogenic variant has been described in individuals with: \n\u2022 Tyroid nodules, including benign follicular adenomas and nodules of indeterminate cytology;   \n\u2022 Diferentiated thyroid cancer, ofen low-invasive, encapsulated, follicular variant of papillary thyroid cancer or minimally invasive follicular thyroid cancer, to solid-variant and poorly diferentiated follicular thyroid carcinoma associated with spindle cell sarcoma with rhabdomyosarcoma diferentiation [Ravella et al 2018, Wasserman et al 2018, Yang et al 2018];   \n\u2022 Wilms tumor. \nGLOW syndrome (global developmental delay, lung cysts, overgrowth, Wilms tumor). Two children with somatic mosaicism for a DICER1 pathogenic variant in the RNase IIIb domain were described with developmental delay, very large, multiple lung cysts, overgrowth, macrocephaly, and bilateral Wilms tumor [Klein et al 2014]. Te phenotype was hypothesized to arise from activation of the PI3K/AKT/mTOR pathway [Klein & Martinez-Agosto 2020]. Five children with mosaic RNase IIIb domain pathogenic variants harbored signifcantly more disease foci than children with DICER1 germline loss-of-function variants [Brenneman et al 2015] and had a signifcantly earlier mean age of diagnosis. A detailed study of four children with somatic mosaicism for a DICER1 pathogenic variant in RNase IIIb domain showed it to be an important cause of more severe DICER1-associated phenotypes, including higher tumor burden [de Kock et al 2016]. \nGenotype-Phenotype Correlations \nA higher number of disease foci and overgrowth have been observed in individuals with mosaicism for DICER1 pathogenic variant in the RNase IIIb domain. No other genotype-phenotype correlations have been identifed. \nPenetrance \n",
      "token_count": 482,
      "sentence_count": 15
    },
    {
      "id": "pp-blastoma_txt_41",
      "contents": " Tyroid Nodules and Diferentiated Tyroid Cancer Guidelines Pocket Card. (Available online for purchase). Accessed 1-13-22. \n",
      "token_count": 30,
      "sentence_count": 3
    },
    {
      "id": "hgc_txt_11",
      "contents": "\u2022 Individuals with a CDH1 pathogenic variant are at risk for extragastric cancers (e.g., lobular breast cancer, colorectal cancer) and should follow screening recommendations for these cancers. \nBreast cancer. Referral to a high-risk breast clinic is recommended. Prophylactic mastectomy may be considered in women heterozygous for a CDH1 germline pathogenic variant. Te authors are aware of a very limited number of women who have undergone prophylactic mastectomy for this reason [Brandberg et al 2008]. \nPrevention of Secondary Complications \nA multidisciplinary team including a surgeon, gastroenterologist, and dietician should provide postoperative care for an individual undergoing PTG (see Prevention of Primary Manifestations). \nSurveillance \nSee Fitzgerald et al [2010] (full text) and van der Post et al [2015] (full text). \nGastric Cancer \nTe optimal surveillance of individuals with a CDH1 germline pathogenic variant is controversial because of the unproven beneft of screening. \nEndoscopy permits direct inspection and biopsy of suspicious areas; however, difuse gastric cancer is difcult to detect at an early, treatable stage because the lesions tend to spread in the submucosa rather than as exophytic masses. Te submucosal lesions are difcult to identify; an additional challenge is sampling bias in a macroscopically normal-appearing gastric mucosa. Terefore, difuse gastric cancer is ofen not detected until it reaches an advanced, incurable stage. \nAt-risk individuals who are not ready to undergo PTG should be screened using the Cambridge protocol [Barber et al 2008]: \n\u2022 Detailed 30-minute upper endoscopy every six to 12 months with multiple random biopsies and biopsies of subtle lesions \u2022 Screening beginning fve to ten years prior to the earliest cancer diagnosis in the family \nMi et al [2018] evaluated the utility of endoscopic surveillance in individuals with an identifed CDH1 pathogenic variant who were delaying PTG and a group with clinically diagnosed HDGC but no identife d CDH1 pathogenic variant. Te authors used autofuorescence imaging and narrow-band imaging with random biopsies; surveillance was performed by the same group of specialists on all individuals.",
      "token_count": 491,
      "sentence_count": 19
    },
    {
      "id": "men1_txt_16",
      "contents": "\u2022 Lipomas are benign fatty tissue tumors found anywhere that fat is located and are present in about $30\\%$ of afected individuals [Takker et al 2012]. Tey can be subcutaneous or, rarely, visceral.   \n\u2022 Other skin fndings include caf\u00e9 au lait macules in $38\\%$ of afected individuals, confetti-like hypopigmented macules in $6\\%$ , and multiple gingival papules in $6\\%$ [Darling et al 1997]. \nCentral nervous system tumors are rare in individuals with MEN1. \n\u2022 Meningioma was reported in $8\\%$ of 74 individuals [Asgharian et al 2004]; the meningiomas were mainly asymptomatic and $60\\%$ showed no growth.   \n\u2022 Ependymoma is present in about $1\\%$ of afected individuals. \nLeiomyomas are benign neoplasms derived from smooth (nonstriated) muscle [McKeeby et al 2001, Ikota et al 2004]. Sporadic uterine leiomyomas afect $20\\%{-30\\%}$ of reproductive-age women. No data regarding the frequency of leiomyomas in women with MEN1 versus sporadic incidence are available \u2013 nor is any data regarding multiple leiomyomas of the esophagus and lungs in individuals with MEN1. \nTyroid tumors. Adenomas, colloid goiters, and carcinomas have been reported to occur in more than $25\\%$ of individuals with MEN1. Te presence of thyroid abnormalities may be incidental and not signifcan t, considering the high prevalence of thyroid disorders in the general population [Takker et al 2012]. \nBreast cancer. A signifcantly higher incidence of breast cancer was found in four independent MEN1 cohorts from the Netherlands, France, Tasmania, and the United States. In the Dutch cohort, the relative risk for breast cancer in females with MEN1 was 2.83; the median age of breast cancer diagnosis was 45 years, approximately 15 years younger than in the general Dutch population [Dreijerink et al 2014]. \nMorbidity and Mortality of MEN1 \n",
      "token_count": 472,
      "sentence_count": 17
    },
    {
      "id": "carney_txt_2",
      "contents": " Once the PRKAR1A pathogenic variant has been identifed in an afected family member, predictive testing for at-risk family members and prenatal and preimplantation genetic testing are possible. \nDiagnosis \nConsensus clinical diagnostic criteria for Carney complex (CNC) have been published [Mateus et al 2008].   \nCriteria are reprinted with permission from Elsevier Publishing. \nSuggestive Findings \nCNC should be suspected in individuals with any of the following major diagnostic criteria with or without additional common fndings. \nMajor diagnostic criteria \n\u2022 Spotty skin pigmentation with typical distribution (lips, conjunctiva and inner or outer canthi, vaginal and penile mucosa)   \n\u2022 Myxoma \\* (cutaneous and mucosal)   \n\u2022 Cardiac myxoma\u00a0\\*   \n\u2022 Breast myxomatosis \\* or fat-suppressed MRI fndings suggestive of this diagnosis   \n\u2022 Primary pigmented nodular adrenocortical disease (PPNAD) \\* or paradoxic positive response of urinary glucocorticosteroid excretion to dexamethasone administration during Liddle's test   \n\u2022 Acromegaly as a result of growth hormone (GH)-producing adenoma\u00a0\\*   \n\u2022 Large cell calcifying Sertoli cell tumor (LCCSCT) \\* or characteristic calcifcation on testicular ultrasound   \nTyroid carcinoma \\* or multiple, hypoechoic nodules on thyroid ultrasound in a child younger than age 18 years   \n\u2022 Psammomatous melanotic schwannoma (PMS)\u00a0\\*   \n\u2022 Blue nevus, epithelioid blue nevus\u00a0\\*   \n\u2022 Breast ductal adenoma\u00a0\\*   \n\u2022 Osteochondromyxoma\u00a0\\*   \n\u2022 Family history of CNC consistent with autosomal dominant inheritance (e.g., afected males and females in multiple generations) \n\nNote: Criteria denoted by \\* are based on histologic confrmation. \nAdditional possible associations or symptoms \n\u2022 Intense freckling (without darkly pigmented spots or typical distribution)   \n\u2022 Multiple blue nevi, common type   \n\u2022 Caf\u00e9 au lait macules or other \"birthmarks\"   \n",
      "token_count": 451,
      "sentence_count": 25
    },
    {
      "id": "mirror_txt_8",
      "contents": "Te term \"bimanual synergia\" is mentioned in OMIM as having been used by William Bateson (1861-1926) in a family with CMM of apparent autosomal dominant inheritance and incomplete penetrance (OMIM 157600). \nPrevalence \nCongenital mirror movements is a very rare disorder, with an estimated prevalence of <1:1,000,000 (Orphanet 238722; accessed 9-21-20), although the actual prevalence could be signifcantly higher due to underdiagnosis, especially in individuals with milder manifestations. \nGenetically Related (Allelic) Disorders \nDCC \n\u2022 Isolated ACC. Heterozygous pathogenic variants in DCC can result in isolated ACC without congenital mirror movements (CMM) [Marsh et al 2017].   \n\u2022 Familial horizontal gaze palsy with progressive scoliosis with impaired intellectual development (OMIM 617542), also known as split-brain syndrome, is a recessive disorder caused by biallelic loss-offunction variants in DCC. Afected individuals have no commissure between the right and lef brain hemispheres, and they exhibit intellectual disability, horizontal gaze palsy, and scoliosis [Jamuar et al 2017]. Sporadic tumors (including colorectal and esophageal cancer) occurring as single tumors in the absence of any other fndings of CMM frequently harbor somatic variants in DCC that are not present in the germline. In these circumstances predisposition to these tumors is not heritable. For more information, see Cancer and Benign Tumors. \nNTN1. No phenotypes other than the one discussed in this GeneReview are proven to be associated with pathogenic variants in NTN1. \nRAD51 \n\u2022 Fanconi anemia, complementation group R (OMIM 617244), is characterized by physical abnormalities such as short stature and microcephaly, bone marrow failure, and predisposition to cancer. It is inherited in an autosomal dominant manner due to dominant-negative RAD51 variants. Sporadic tumors (including breast cancer) occurring as single tumors in the absence of any other fndin gs of CMM may harbor somatic variants in RAD51 that are not present in the germline. In these circumstances predisposition to these tumors is not heritable.",
      "token_count": 495,
      "sentence_count": 15
    },
    {
      "id": "retinoblastoma_txt_1",
      "contents": "$ Individual with unilateral retinoblastoma or retinoma with no germline RB1 pathogenic variant identifed on molecular genetic testing; residual risk of mosaicism is ${<}1\\%$ .) \n\u2022 H1. Individual with bilateral retinoblastoma, trilateral retinoblastoma (retinoblastoma with intracranial central nervous system midline embryonic tumor), retinoblastoma and a family history of retinoblastoma, or identifcation of a germline RB1 pathogenic variant \nManagement \nTreatment of manifestations: Early diagnosis and treatment of retinoblastoma can reduce morbidity and increase longevity; care is best provided by multidisciplinary teams of specialists including ophthalmology, pediatric oncology, pathology, and radiation oncology. Treatment options depend on tumor stage, number of tumor foci (unifocal, unilateral multifocal, or bilateral), localization and size of the tumor(s) within the eye(s), presence of vitreous seeding, potential for useful vision, extent and kind of extraocular extension, and resources available. Treatment options include enucleation; cryotherapy; laser; systemic or local ocular chemotherapy, including intra-arterial chemotherapy, combined with or followed by laser or cryotherapy; radiation therapy using episcleral plaques; and, as a last resort, external beam radiotherapy. Standard treatments for non-ocular neoplasms. \nSurveillance: Individuals with an RB1 germline pathogenic variant (H1) should have eye examinations (under anesthesia in young children) every three to four weeks until age six months, every two months until age three years, every three to six months until age seven years, annually until age ten years, and then every two years in order to identify a retinoblastoma as early as possible. In individuals with unilateral retinoblastoma without an identifed heterozygous germline RB1 pathogenic variant $(\\mathrm{H}0^{\\ast})$ , clinical eye examination and eye ultrasound every three to six months until age seven years, then every two years. In individuals with retinomas, retinal examinations and imaging every one to two years.",
      "token_count": 496,
      "sentence_count": 9
    },
    {
      "id": "brca1_txt_8",
      "contents": " An excess of serous adenocarcinomas as opposed to mucinous or borderline tumors have been observed in women with germline BRCA1 or BRCA2 pathogenic variants [Liu et al 2012, McLaughlin et al 2013]. Serous adenocarcinomas are generally of higher grade and exhibit prominent intraepithelial lymphocytes, marked nuclear atypia, and abundant mitoses [Fujiwara et al 2012]. Most high-grade serous cancers arise from the fallopian tubes rather than the ovaries [Daly et al 2015]. \nStudies on ovarian cancer survival in women with a germline BRCA1 or BRCA2 pathogenic variant have yielded conficting results. A pooled analysis of 26 observational studies found a more favorable survival rate among individuals with a BRCA1 or BRCA2 pathogenic variant compared to individuals without a BRCA1 or BRCA2 pathogenic variant. Tese results persisted when controlling for stage, grade, histology, and age at diagnosis [Bolton et al 2012]. A large population-based case-control study found a higher response to platinum-based therapy, longer progression-free survival, and improved overall survival among individuals with a germline BRCA1 or BRCA2 pathogenic variant [Alsop et al 2012]. Similarly, individuals with platinum-sensitive epithelial ovarian tumors were more likely to have a germline BRCA1 or BRCA2 pathogenic variant than individuals with platinum-resistant tumors [Dann et al 2012]. In a large series of unselected individuals with ovarian cancer, the short-term survival of individuals with ovarian cancer with a germline BRCA1 or BRCA2 pathogenic variant was better than that of individuals without an identifed BRCA1 or BRCA2 pathogenic variant; however, the survival advantage was short lived and did not lead to a long-term survival beneft [McLaughlin et al 2013]. \n\nMale breast cancer. Te majority of BRCA1- and BRCA2-associated male breast cancers, particularly those associated with BRCA2 pathogenic variants, are high grade, hormone receptor positive, and associated with lymph node metastases.",
      "token_count": 467,
      "sentence_count": 11
    },
    {
      "id": "hgc_txt_5",
      "contents": " Te fve-year survival rate drops below $30\\%$ when the diagnosis is made at a late stage [Stiekema et al 2013]. \nIf gastric cancer is detected early and resected, the fve-year survival rate is $90\\%$ . Because early detection of DGC is difcult, survival of individuals with CDH1 pathogenic variants is believed to be the same as in individuals with sporadic DGC. Terefore, in individuals with a CDH1 germline pathogenic variant, clinical management options include prophylactic gastrectomy and an intensive regimen of endoscopic surveillance. \nApart from the two of 17 individuals who had prophylactic gastrectomy and previous Helicobacter pylori infection on serologic testing [Blair et al 2006], there is no evidence of increased rates of $H\\,p.$ ylori infection associated with the microscopic DGCs in the prophylactic gastrectomy specimens of individuals with a germline CDH1 pathogenic variant. \nPathology. In DGC, loss of the E-cadherin protein causes the individual tumor cells to grow and invade neighboring structures. Te individual malignant cells infltrate and spread under histologically normal-looking mucosa causing widespread thickening and rigidity of the gastric wall, a phenomenon known as linitis plastica [McColl 2006]. No tumor mass is formed, unlike that of the intestinal type. Te malignant cells have a distinctive signet ring appearance, which is caused by an accumulation of intracellular mucin that pushes the nucleus to one side. A clearly defned preneoplastic lesion is not seen in DGC. A progression model for DGC developed from studying prophylactic total gastrectomy (PTG) specimens from individuals with a germline CDH1 pathogenic variant describes isolated neoplastic signet ring cells at the base of the glands and pagetoid spread of signet ring cells below the preserved epithelium of glands/foveolae into the stroma [Carneiro et al 2004]. \nGenotype-Phenotype Correlations \nNo genotype-phenotype correlations have been reported to date. \nPenetrance \nTe penetrance of HDGC is incomplete.",
      "token_count": 485,
      "sentence_count": 15
    },
    {
      "id": "pp-blastoma_txt_36",
      "contents": "\" Tese somatic pathogenic variants lead to defective production of mature miRNAs from the $5^{\\prime}$ (5p) end of the miRNA hairpin but preserve the cleavage of the $3^{\"}$ (3p) end of the hairpin [Gurtan et al 2012, Anglesio et al 2013, Pugh et al 2014]. \nExamples of somatic DICER1 variants identifed in other tumors: \n\u2022 Nearly all Sertoli-Leydig cell tumors and gynandroblastoma (based on tumor testing) [Schultz et al 2017], half of which are associated with a germline or mosaic DICER1 pathogenic variant \n\u2022 Tree out of 15 $(20\\%)$ PPBs with tumor-specifc loss-of-function and missense pathogenic variants in DICER1 with normal germline [Pugh et al 2014]   \n\u2022 Eighteen out of 20 $(90\\%)$ CNs with loss-of-function pathogenic variants in $70\\%$ (14/20); however, germline DNA was not examined [Doros et al 2014].   \n\u2022 Two out of 52 $(4\\%)$ ERMS tumors with loss-of-function pathogenic variants; however, germline DNA was not examined [Doros et al 2012].   \n\u2022 Two pineoblastomas from children with a germline DICER1 pathogenic variant did not have a tumorspecifc somatic missense pathogenic variant, suggesting an alternate tumorigenesis pathway [Sabbaghian et al 2012].   \n\u2022 Ninety-fve percent of primary intracranial sarcomas in children [Koelsche et al 2018]   \n\u2022 Multiple cases of nasal chondromesenchymal hamartoma. A systematic review of the literature identife d 48 cases of NCMH [Mason et al 2015].   \n\u2022 Tyroid nodules with indeterminate cytology and a spectrum of disease that spans the range from benign follicular adenomas to diferentiated thyroid cancer and rarely poorly diferentiated thyroid cancer [Ravella et al 2018, Wasserman et al 2018, Yang et al 2018, Chernock et al 2020] \nChapter Notes \nAuthor Notes \n",
      "token_count": 477,
      "sentence_count": 13
    },
    {
      "id": "isselbacher-et-al-2022-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the_txt_174",
      "contents": "20-22 Extension to the groin increases the risk of subsequent infection. Although some studies suggest a lower risk with endovascular versus open repair, the EVAR-1 (UK Endovascular Aneurysm Repair 1) RCT and a large Medicare analysis found equivalent rates of graft infection.23-25 Common sources of infection include: contamination at the time of implantation; graft enteric erosion or fistula to adjacent bowel, esophagus, or airway; or, rarely, hematogenous spread from remote infection. Suspicion is usually raised by symptoms, laboratory test abnormalities, or axial imaging findings. In the presence of an aortic graft infection, no surgical option is clearly superior. Basic tenets are to remove all infected tissue, including the graft and surrounding tissue, reconstruction of distal flow either as an extra-anatomic or in situ bypass, and coverage of the contaminated field with omentum, muscle flaps, or pleura. Previously, extra-anatomic bypass followed 24 to 48 hours later by graft explant and oversewing of the aortic stump was considered the gold standard for abdominal aortic infection but is usually not appropriate for the thoracic aorta. Aortic allografts, deep vein, and silver-impregnated or rifampin-soaked prosthetic grafts placed in situ have all shown good results as well, often with lower complication rates. A 6-week course of intravenous antibiotics is typically used, sometimes followed by long-term oral suppressive therapy. \n\nRecommendation-Specific Supportive Text \n1. Early graft infection $(\\leq\\mathsf{3}\\,\\,\\mathsf{m o})$ is often associated with fever and back pain, whereas late graft infections $(>\\!3\\,\\,\\mathsf{m o})$ may have an insidious onset with symptoms of fatigue and malaise, or may have fever, an elevated white blood cell count, erythrocyte sedimentation rate, C-reactive protein, or advanced signs of sepsis with hemodynamic instability or frank hemorrhage from rupture or fistulae to adjacent bowel, esophagus, or airway.",
      "token_count": 480,
      "sentence_count": 12
    },
    {
      "id": "cyld-cs_txt_7",
      "contents": "\" Each cluster consists of darker, basophilic cells at the periphery, and larger pale cells centrally and is surrounded by a thick, hyaline membrane consisting of extracellular matrix proteins (including collagen IV and VII and laminin-332) in the basement membrane of the skin (see Figure 2a). \n\nSpiradenomas \nSpiradenomas are nodular tumors that are ofen blue/black in color. Tey tend to be painful and can grow up to $10\\;\\mathrm{cm}$ in diameter (see Figure 3). \nHistopathology. Spiradenomas are relatively disorganized histologically when compared to cylindromas and consist of sheets of epithelial cells associated with a lymphocytic infltrate (mixed T and B cells). Some afecte d individuals present with histologic features of both cylindroma and spiradenoma within a single tumor specimen, giving rise to the term spiradenocylindroma. In addition, there is evidence that histologically organized cylindroma and histologically disorganized spiradenoma represent extremes of a spectrum of histophenotype of the same tumor [Rajan et al 2011a] (see Figure 2b). \nTrichoepitheliomas \nTrichoepitheliomas are skin-colored papules or frm nodules, mainly found on the central face (see Figure 4).   \nTey are ofen symmetrically distributed and usually no more than $2{-}5\\;\\mathrm{mm}$ across. \nHistopathology. Trichepitheliomas demonstrate clusters of basaloid germinative cells with keratinizing cystic spaces and superfcial follicular diferentiation surrounded by a fbrocytic stroma. Intra-stromal clefs and mesenchymal papillary buds may be seen. \nOther Findings \nSalivary lesions. Afected individuals are also at risk of developing tumors of the salivary glands, typically membranous basal cell adenoma (MBCA) [Jungeh\u00fclsing et al 1999] usually afer age 40 years. \n",
      "token_count": 469,
      "sentence_count": 17
    },
    {
      "id": "fap_txt_8",
      "contents": " According to the international collaborative study by Knudsen et al [2010], attenuated FAP was clinically defned as individuals with $\\le\\!100$ colorectal adenomatous polyps at age ${\\geq}25$ years. Polyps tend to occur more proximally in the colon than in classic FAP. Te average age of CRC diagnosis in individuals with attenuated FAP is 50 to 55 years \u2013 ten to 15 years later than in classic FAP, but earlier than in those with sporadically occurring CRC [Spirio et al 1993, Giardiello et al 1997]. Te cumulative risk for CRC by age 80 years in attenuated FAP is estimated at $70\\%$ [Neklason et al 2008]. \nOther Features Variably Present in FAP \nSmall-bowel polyps and cancer. Adenomatous polyps of the duodenum, observed in $50\\%.90\\%$ of individuals with FAP, are commonly found in the second and third portions of the duodenum [Kadmon et al 2001] and to a variable degree in the jejunum or ileum [Koornstra 2012]. A classifcation system for duodenal polyps, based on number and size of polyps, histology, and degree of dysplasia, has been developed [Spigelman et al 1989]. No clear association between the number of colonic polyps and the number of upper gastrointestinal polyps has been identifed [Kadmon et al 2001]. \nAdenomatous polyps of the periampullary region (including the duodenal papilla and ampulla of Vater), some of which can be endoscopically subtle or invisible, are seen in at least $50\\%$ of individuals with FAP, [Mehta et al 2021]. Polyps in this area can cause obstruction of the pancreatic duct resulting in pancreatitis or biliary obstruction, both of which occur at increased frequency in individuals with FAP. Tese polyps are ofen small and require either a distal attachment cap-assisted gastroscope or side-viewing endoscope for visualization [Yang et al 2020]. Some theorize that pancreaticobiliary secretions (e.g.",
      "token_count": 498,
      "sentence_count": 15
    }
  ]
}